Completed PHASE3 INTERVENTIONAL 2-arm NCT00373256

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer

Sponsor: Pfizer

Conditions Breast Neoplasms

Interventions Sunitinib bevacizumab paclitaxel

Updated 6 times since 2017 Last updated: Sep 5, 2012 Started: Nov 30, 2006 Primary completion: Jun 30, 2009 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00373256, this PHASE3 trial focuses on Breast Neoplasms and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Allentown, United States , Amarillo, United States , Anaheim, United States , Annapolis, United States , Antioch, United States , Antonio, United States , Arlington, United States , Atlanta, United States , Aurora, United States and 180 more locations